Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Forecast Report: Size, Share, and Opportunities 2029

 Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

What Is the Estimated Market Size and CAGR of the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market for the Period 2025–2029?
The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market size has grown strongly in recent years. It will grow from $5.57 billion in 2024 to $5.97 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing prevalence of PNH and aHUS, rising investment in rare disease research, growing demand for targeted therapies, rising awareness about PNH and aHUS, and growing adoption of complement inhibitors.

The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market size is expected to see strong growth in the next few years. It will grow to " $7.88 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing regulatory approvals for new treatments, growing collaboration between biotech companies and research institutes, rising demand for personalized medicine, increasing investment in rare disease startups, and a rising number of clinical trials and research studies. Major trends in the forecast period include advancements in complement inhibition therapies, integration of gene therapy approaches, developments in personalized medicine, technology-driven diagnostic tools, and technology integration for remote patient monitoring.

Get your free report sample today:
PNH And AHUS Market Growth, Drivers Report 2025 To 2034 Sample

Which Core Drivers Are Expected to Drive Demand Within the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
The rising prevalence of rare diseases is expected to propel the growth of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market going forward. Rare diseases are medical conditions that affect a small percentage of the population, typically fewer than 200,000 individuals, and are often characterized by their complexity, severity, and the need for specialized treatment. The increasing prevalence of rare diseases can be attributed to advancements in diagnostic technologies, which enable better detection and identification of previously underreported or undiagnosed conditions. Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) contribute to the understanding and treating rare diseases by providing insights into the pathophysiology and potential therapeutic targets for conditions with limited treatment options. For instance, in November 2024, according to the Food and Drug Administration, a US-based federal agency, more than 7,000 rare diseases impacted over 30 million individuals in the United States. Therefore, the rising prevalence of rare diseases is driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market.

What Are the Primary Market Segments in the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)market covered in this report is segmented –

1) By Type: Soliris; Ultomiris
2) By Disease Type: Paroxysmal Nocturnal Hemoglobinuria(PNH); Atypical Hemolytic Uremic Syndrome(aHUS)
3) By Treatment Type: Complement Inhibitors; Plasma Exchange Or Infusion; Other Symptomatic Treatments
4) By Diagnosis Method: Clinical Diagnosis; Genetic Testing; Biomarker Testing
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other Users

Subsegments:
1) By Soliris: Eculizumab For PNH; Eculizumab For aHUS; Eculizumab Biosimilars
2) By Ultomiris: Ravulizumab For PNH; Ravulizumab For aHUS; Ravulizumab Extended-Interval Dosing

Which Emerging Trends Are Shaping the Future of the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market are focusing on developing innovative products, such as complement inhibitors, to improve treatment outcomes and patient convenience. Complement inhibitors are therapeutic agents that block specific components of the complement system, a part of the immune system that helps clear pathogens and damaged cells. For instance, in December 2023, Novartis AG, a Switzerland-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Fabhalta (iptacopan), the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria, and provides superior hemoglobin improvement without the need for transfusions. This innovative complement inhibitor works by inhibiting Factor B in the alternative complement pathway, providing comprehensive control of both intravascular and extravascular hemolysis. Its oral administration simplifies disease management and improves the quality of life for patients, eliminating the burdens associated with frequent infusions.

Who Are the Major Companies Operating in the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market are Roche Holding AG, AstraZeneca plc, Novartis AG, Amgen Inc., Teva Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Alexion Pharmaceuticals Inc., UCB Pharma Limited, Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Genentech Inc., Omeros Corporation, CinnaGen Co., Apellis Pharmaceuticals Inc., CANbridge Pharmaceuticals Inc., Kira Pharmaceuticals, NovelMed Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Akari Therapeutics plc

Get the detailed paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market report today
PNH And AHUS Market Growth, Drivers Report 2025 To 2034

Which Region Holds the Largest Share of the Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:
The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn